Goldman Sachs lowers Regenxbio stock price target on regulatory uncertainty
Goldman Sachs lowers Regenxbio stock price target on regulatory uncertainty
Goldman Sachs lowers Regenxbio stock price target on regulatory uncertainty
Latest in Markets
-
Dominari Holdings reports 9x return on Cerebras investment
-
UroGen’s UGN-103 shows 94.5% response durability in trial
-
LanzaTech raises $20 million in registered direct offering
-
Form DEF 14C BEASLEY BROADCAST GROUP For: 15 May
-
Tandem Diabetes Care to end employment of chief commercial officer
-
Playtech chairman purchases 57,000 shares for £193,667
Summary aggregated from Investing.com's public RSS feed. The full reporting belongs to Investing.com — please read it on their site.